Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Gemcitabine

5

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

2
Last update : 17/08/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
Journal of cancer research and clinical oncology 2011 Oct;137;1469-75 2011 Oct
An autopsy case of acute pulmonary toxicity associated with gemcitabine.
Internal medicine (Tokyo, Japan) 2003 Oct;42;1022-5 2003 Oct
Diffuse alveolar damage in a patient treated with gemcitabine.
The European respiratory journal 1998 Feb;11;504-6 1998 Feb
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
Cancer 1997 Jul 15;80;286-91 1997 Jul 15

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies